Samuel Kintz
President and CEO at Enliven Therapeutics Inc.
Sits on 1 board. Last updated September 27, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Enliven Therapeutics Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Enliven Therapeutics Inc. June 23, 2023100.0%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 17, 2025 | Enliven Therapeutics Inc. | Open-market sale | −12,500 | $21.82 | $272,750 |
| Oct 17, 2025 | Enliven Therapeutics Inc. | Open-market sale | −12,500 | $21.33 | $266,625 |
| Sep 26, 2025 | Enliven Therapeutics Inc. | Open-market sale | −3,700 | $20.06 | $74,222 |
| Sep 23, 2025 | Enliven Therapeutics Inc. | Open-market sale | −2,800 | $20.03 | $56,084 |
| Sep 19, 2025 | Enliven Therapeutics Inc. | Open-market sale | −1,000 | $20.25 | $20,250 |
| Sep 17, 2025 | Enliven Therapeutics Inc. | Open-market sale | −5,000 | $19.09 | $95,450 |
| Aug 19, 2025 | Enliven Therapeutics Inc. | Open-market sale | −590 | $20.00 | $11,800 |
| Aug 18, 2025 | Enliven Therapeutics Inc. | Open-market sale | −10,393 | $20.02 | $208,068 |
| Jul 17, 2025 | Enliven Therapeutics Inc. | Open-market sale | −4,150 | $21.58 | $89,557 |
| Jul 17, 2025 | Enliven Therapeutics Inc. | Open-market sale | −4,687 | $22.69 | $106,348 |
| Jul 17, 2025 | Enliven Therapeutics Inc. | Open-market sale | −3,663 | $23.37 | $85,604 |
| Jun 17, 2025 | Enliven Therapeutics Inc. | Open-market sale | −10,502 | $22.08 | $231,884 |
| Jun 17, 2025 | Enliven Therapeutics Inc. | Open-market sale | −1,998 | $22.75 | $45,455 |
| Jun 3, 2025 | Enliven Therapeutics Inc. | Open-market sale | −7,500 | $20.05 | $150,375 |
| May 19, 2025 | Enliven Therapeutics Inc. | Open-market sale | −5,000 | $16.49 | $82,450 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.